Revive Therapeutics (FRA:31R) Total Liabilities : €2.38 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics Total Liabilities?

Revive Therapeutics's Total Liabilities for the quarter that ended in Mar. 2025 was €2.38 Mil.

Revive Therapeutics's quarterly Total Liabilities increased from Sep. 2024 (€2.19 Mil) to Dec. 2024 (€2.23 Mil) and increased from Dec. 2024 (€2.23 Mil) to Mar. 2025 (€2.38 Mil).

Revive Therapeutics's annual Total Liabilities declined from Jun. 2022 (€3.30 Mil) to Jun. 2023 (€2.50 Mil) and declined from Jun. 2023 (€2.50 Mil) to Jun. 2024 (€2.31 Mil).

Revive Therapeutics Total Liabilities Historical Data

The historical data trend for Revive Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Total Liabilities Chart

Revive Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

0.55

0.68

3.30

2.50

2.31

Revive Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															2.26	2.31	2.19	2.23	2.38

Revive Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Revive Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.253	+	(0	+	0.054
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.31

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	7.21	-	4.902
	=	2.31

Revive Therapeutics's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.279	+	(0.043	+	0.053
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2.38

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	6.204	-	3.829
	=	2.38

Revive Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RVVTF:USA RVV:Canada

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Revive Therapeutics Headlines

No Headlines